Clinical Research Protocols
Clinical Research Protocols for Bladder Cancer
Compiled by Margaret Gross-King, RN, MS, OCN
Clinical Research Manager, H. Lee Moffitt Cancer Center & Research Institute
This list of clinical research protocols relating to bladder cancer is compiled for
your convenience.
Editor's note: This compilation of clinical research protocols emphasizes the NCI
high-priority studies, other bladder preservation studies, and new approaches for advanced
bladder cancer that are active in the United States. For studies in other urologic cancers
or for studies outside of the United States, contact PDQ.
NCI High Priority Studies
SWOG8710 INT0080 Phase III Randomized Comparison of Cystectomy Alone vs
Neoadjuvant MVAC (MTX/VBL/DOX/CDDP) Plus Cystectomy in Patients With Locally Advanced
Transitional Cell Carcinoma of the Bladder (Summary last modified 05/96).
Chairman: Robert B. Natale, University of Southern California School of Medicine, Los
Angeles, Calif. Lead organization: Southwest Oncology Group. Acceptable age range: any
age.
Other Bladder Preservation Studies
MDAID94027 NCIT940174D Phase III Randomized Study of MVAC
(MTX/VBL/DOX/CDDP) With vs Without Radiotherapy Following TURBT for Bladder Cancer With
Early Muscle Invasion (Summary last modified 06/96).
Chairman: Alan Pollack, University of Texas M.D. Anderson Cancer Center, Houston,
Tex. Lead organization: University of Texas M.D. Anderson Cancer Center. Acceptable age
range: no age specified.
RTOG9506 Phase I/II Multimodal Therapy for Stage II/III Bladder Cancer
Following TUR: Induction With CDDP/5FU/Irradiation (CFI) Followed by Consolidation CFI
for Complete Responders or by Radical Cystectomy for Residual Disease (Summary last
modified 12/95).
Chairman: William U. Shipley, Massachusetts General Hospital Cancer Center, Boston,
Mass. Lead organization: Radiation Therapy Oncology Group. Acceptable age range: 18 and
over.
SWOG9312 Phase II Study of CDDP/5FU Plus Radiotherapy for Locally Advanced
or Inoperable Bladder Cancer (Summary last modified 01/95).
Chairman: Maha Hadi A. Hussain, Veterans Administration Medical Center Detroit,
Mich. Lead organization: Southwest Oncology Group. Acceptable age range: adult.
SWOG8733 Phase II Pilot Evaluation of Preoperative Radiotherapy Plus 5FU as
a BladderPreserving Regimen (With Cystectomy for Nonresponders) in Patients With
Operable Bladder Cancer and Radiotherapy Plus 5FU Alone in Patients With Inoperable
Bladder Cancer (Summary last modified 04/93).
Chairman: Kenneth J. Russell, University Cancer Center, University of Washington
Medical Center, Seattle, Wash. Lead organization: Southwest Oncology Group. Acceptable age
range: 21 and over.
Advanced Bladder Cancer Studies
E1896 Phase II Study of VIG (VBL/IFF/GAN) for Advanced Squamous Cell Carcinoma
and Adenocarcinoma of the Urothelium (Summary last modified 09/96).
Chairman: Robert Dreicer, University of Iowa Hospitals and Clinics, Iowa City, Iowa.
Lead organization: Eastern Cooperative Oncology Group. Acceptable age range: 18 and over.
E2895 Phase II Study of CDDP/TAX in Advanced Urothelial Carcinoma (Summary
last modified 08/96).
Chairman: Robert Dreicer, University of Iowa Hospitals and Clinics, Iowa City, Iowa.
Lead organization: Eastern Cooperative Oncology Group. Acceptable age range: 18 and over.
E2896 Phase II Study of CBDCA/TAX in Advanced Urothelial Carcinoma With Renal
Insufficiency (Summary last modified 09/96).
Chairman: Robert L. Comis, Thomas Jefferson University Hospital, Philadelphia, Pa. Lead
organization: Eastern Cooperative Oncology Group. Acceptable age range: 18 and over.
LACUSC0C942 NCIT950081H Phase I Pharmacodynamic Study Randomized
for Sequence of Administration of HU and 5FU for Advanced Solid Tumors (Summary last
modified 08/96).
Chairman: Colin Paul Spears, University of Southern California School of Medicine, Los
Angeles, Calif. Lead organization: USC/Norris Comprehensive Cancer Center. Acceptable age
range: 18 and over.
MSKCC95031 NCIV950743 Phase II Study of CDDP/IFF/TAX in Advanced
Urothelial Tumors (Summary last modified 10/95).
Chairman: Dean F. Bajorin, Memorial SloanKettering Cancer Center, New York, NY. Lead
organization: Memorial SloanKettering Cancer Center. Acceptable age range: 18 and over.
SWOG9457 Phase II Study of Paclitaxel/Carboplatin for Advanced Transitional
Cell Carcinoma of the Urothelium (Summary last modified 09/96).
Chairman: Eric J. Small, UCSF/
Mount Zion Medical Center, San Francisco, Calif. Lead organization: Southwest Oncology
Group. Acceptable age range: adult.
Legend for Abbreviations:
E = Eastern Cooperative Oncology Group
LAC-USC = University of Southern California
MDA-ID = M.D. Anderson Cancer Center
MSKCC = Memorial Sloan-Kettering Cancer Center
RTOG = Radiation Therapy Oncology Group
SWOG = Southwest Oncology Group
For more information on these protocols, please call PDQ, a service of the National
Cancer Institute, at 1-800-4-CANCER.
Back to Cancer Control Journal
Volume 3 Number 6